US FDA panel votes against approval of Intercept fatty liver drug, cites safety issues
A panel of advisers to the U.S. Food and Drug Administration, wary of the safety of Intercept Pharmaceuticals' oral drug for a type of fatty liver disease, recommended on Friday holding off on an accelerated approval of the medicine.